Xiangxue Pharmaceutical
Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet s… Read more
Xiangxue Pharmaceutical (300147) - Total Liabilities
Latest total liabilities as of September 2025: CN¥6.27 Billion CNY
Based on the latest financial reports, Xiangxue Pharmaceutical (300147) has total liabilities worth CN¥6.27 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Xiangxue Pharmaceutical - Total Liabilities Trend (2007–2024)
This chart illustrates how Xiangxue Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Xiangxue Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Xiangxue Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dom Development S.A.
WAR:DOM
|
Poland | zł4.33 Billion |
|
Konoike Transport Co. Ltd
F:2KT
|
Germany | €136.30 Billion |
|
Wetown Electric Group Co Ltd
SHG:688226
|
China | CN¥3.31 Billion |
|
Mister Car Wash, Inc. Common Stock
NASDAQ:MCW
|
USA | $2.04 Billion |
|
Dat Xanh Real Estate Service Contructions Corp
VN:DXG
|
Vietnam | ₫17.24 Trillion |
|
Hainan Expressway Co Ltd
SHE:000886
|
China | CN¥881.00 Million |
|
Eramet SA
PA:ERA
|
France | €4.39 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Xiangxue Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 9.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xiangxue Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xiangxue Pharmaceutical (2007–2024)
The table below shows the annual total liabilities of Xiangxue Pharmaceutical from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥6.06 Billion | +1.54% |
| 2023-12-31 | CN¥5.97 Billion | -8.68% |
| 2022-12-31 | CN¥6.53 Billion | -14.27% |
| 2021-12-31 | CN¥7.62 Billion | +37.97% |
| 2020-12-31 | CN¥5.53 Billion | +27.01% |
| 2019-12-31 | CN¥4.35 Billion | -5.71% |
| 2018-12-31 | CN¥4.61 Billion | -16.98% |
| 2017-12-31 | CN¥5.56 Billion | +29.10% |
| 2016-12-31 | CN¥4.30 Billion | +289.18% |
| 2015-12-31 | CN¥1.11 Billion | -35.59% |
| 2014-12-31 | CN¥1.72 Billion | -2.70% |
| 2013-12-31 | CN¥1.76 Billion | +24.94% |
| 2012-12-31 | CN¥1.41 Billion | +181.28% |
| 2011-12-31 | CN¥502.16 Million | +5.49% |
| 2010-12-31 | CN¥476.01 Million | +31.97% |
| 2009-12-31 | CN¥360.69 Million | +1.62% |
| 2008-12-31 | CN¥354.94 Million | -1.95% |
| 2007-12-31 | CN¥361.98 Million | -- |